Protective and anti-arrhythmic effects of dauricine and verapamil on acute myocardial infarction in anesthetized dogs.
Dauricine (Dau) 5 mg.kg-1 and verapamil (Ver) 0.15 mg.kg-1 iv followed by infusions of 0.1 and 0.01 mg.kg-1.min-1, respectively, for 30 min, depressed the elevated coronary venous blood LDH and CPK after LAD occlusion. Dau produced antagonistic effects on acute myocardial ischemia-induced ventricular ectopic activities (VE) and ventricular tachycardia (VT). The incidences of VE and VT in Ver group and ventricular fibrillation (VF) in both groups tended to descend. The results suggested that Dau and Ver produced marked protective effects on myocardial infarction and antagonized the acute ischemic arrhythmia.
Zhu
J Q
JQ
Department of Clinical Pharmacology, Tongji Medical University, Hankou, China.
Zeng
F D
FD
Hu
C J
CJ
D000470:Alkaloids; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001145:Arrhythmias, Cardiac / Q000201:enzymology / Q000517:prevention & control*; D044182:Benzylisoquinolines; D003402:Creatine Kinase / Q000097:blood; D004285:Dogs; D005260:Female; D007546:Isoquinolines / Q000494:pharmacology* / Q000627:therapeutic use; D007770:L-Lactate Dehydrogenase / Q000097:blood; D008297:Male; D009203:Myocardial Infarction / Q000201:enzymology / Q000517:prevention & control*; D044005:Tetrahydroisoquinolines; D014700:Verapamil / Q000494:pharmacology* / Q000627:therapeutic use
D000470:Alkaloids; D000889:Anti-Arrhythmia Agents; D044182:Benzylisoquinolines; D007546:Isoquinolines; D044005:Tetrahydroisoquinolines; C035934:dauricine; D014700:Verapamil; D007770:L-Lactate Dehydrogenase; D003402:Creatine Kinase